Professional Summary
Professional Overview
Katherine Harris is a seasoned biopharmaceutical executive with over 15 years of experience in drug discovery and development. As the Chief Development Officer (CDO) at Rondo Therapeutics, she is responsible for leading the company's research and development efforts, driving the advancement of novel therapeutic candidates, and overseeing the successful execution of clinical trials.
Experience Summary
Current Role
As the CDO at Rondo Therapeutics, Katherine is spearheading the company's pipeline of innovative drug candidates, with a focus on developing therapeutics for unmet medical needs. She is responsible for strategically aligning the R&D activities with the company's overall business objectives, ensuring the efficient utilization of resources, and fostering a collaborative environment that promotes scientific excellence and innovation.
Career Progression
Throughout her career, Katherine has demonstrated a strong track record of success in various leadership roles within the biopharmaceutical industry. Prior to her current position, she served as the Vice President of Discovery at Amgen and Teneobio, Inc., where she played a pivotal role in advancing multiple drug candidates from the discovery phase through clinical development. Her extensive experience in discovery research, target validation, and preclinical studies has enabled her to navigate the complex drug development landscape with strategic acumen.
Academic Background
Katherine holds a Ph.D. in Molecular Biology from the University of California, Berkeley, where her research focused on the development of novel therapeutic approaches. She has also published numerous scientific articles in peer-reviewed journals and has been recognized for her contributions to the field.
Areas of Expertise
- Drug discovery and development
- Target identification and validation
- Preclinical research and studies
- Clinical trial design and execution
- Biologics and small molecule therapeutics
- Cross-functional team leadership and collaboration
- Strategic planning and decision-making
Professional Impact
During her tenure at Amgen and Teneobio, Inc., Katherine played a pivotal role in the advancement of several drug candidates, including the successful completion of multiple phase II clinical trials. Her expertise in translating innovative scientific ideas into tangible therapeutic solutions has earned her recognition within the industry. As the CDO at Rondo Therapeutics, Katherine is poised to leverage her extensive experience to drive the company's growth and contribute to the development of cutting-edge therapies that address unmet medical needs.
Conclusion
With her extensive expertise, strategic vision, and proven track record of success, Katherine Harris is well-positioned to lead Rondo Therapeutics' research and development efforts, driving the company's growth and making a meaningful impact on the lives of patients.
